Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says

Executive Summary

CDER Director Janet Woodcock says rare disease advocates should consider organizing patients to study a rare disease history and progression.

You may also be interested in...



Rare Diseases: Growing Understanding Will Unlock Accelerated Approval, FDA Says

US FDA officials say they need knowledge of the disease to have the confidence to use accelerated approval.

Orphan Disease Natural History Grants Latest FDA Incentive For Drug Development

Agency will make $2m available in 2017.

As Orphan Drugs Gain More Attention, FDA Releases Development Guidance

Straightforward draft document seems aimed at entities that have limited experience working with the agency.

Related Content

Topics

UsernamePublicRestriction

Register

PS053944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel